Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PNT2258

Oligonucleotide · Gene silencing: BCL2 · developed by Sierra Oncology LLC - a GSK company

Phase 2 Most advanced trial (none active)
GSK Developer
1 Registered trials

What is PNT2258?

PNT2258 is a liposomal formulation of a 24-mer oligonucleotide that binds complementarily to the untranscribed DNA sequence upstream of BCL2 promoters. It interferes with DNA replication and transcription of the BCL2 gene, which is intended to restore apoptosis in BCL2-overexpressing tumor cells. It is being studied in Richter's Transformation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide
Targets
BCL2
Mechanism
Gene silencing: BCL2
Pathways
apoptosis, DNA replication, transcription
Therapy area
Oncology
Developer
Sierra Oncology LLC - a GSK company (GSK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02226965 Phase 2 Lymphoma, Diffuse Large B-Cell Completed GSK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Richter's Transformation

Other drugs acting on BCL2

More from Sierra Oncology LLC - a GSK company

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the GSK page.

Follow GSK, the company behind PNT2258

See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GSK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.